drugset / Trial / NCT02151474
INCB047986 in Rheumatoid Arthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to explore the safety, tolerability and efficacy of INCB047986, in subjects with moderate to severe rheumatoid arthritis.
Timeline
- Start
- 2014-05
- Primary completion
- 2014-08
- Completion
- 2014-08
Outcome
Outcome not reported
Stopped (Business): “Business decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCB047986 | Unknown | 4 mg | Oral |
| Subject | INCB047986 | Unknown | 8 mg | Oral |
| Subject | INCB047986 | Unknown | 12 mg | Oral |